ORIX Corporation (IX)

Intra-Cellular Therapies Ratios and Metrics

Market cap in millions USD. Fiscal year is April - March.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 5, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Market Capitalization	26,260	23,399	25,113	18,777	23,496	20,560
Market Cap Growth	-6.83%	-6.83%	33.75%	-20.09%	14.28%	35.10%
Enterprise Value	62,922	59,961	59,040	51,313	58,281	54,990
Last Close Price	23.39	20.89	21.43	15.55	18.31	15.54
PE Ratio	11.18	9.97	10.97	8.60	8.99	11.82
PS Ratio	1.37	1.22	1.35	0.94	1.14	0.99
PB Ratio	0.94	0.84	0.94	0.69	0.85	0.73
P/TBV Ratio	1.37	1.22	1.41	1.07	1.24	1.11
P/FCF Ratio	-	-	89.32	-	15.33	6.65
P/OCF Ratio	3.02	2.70	3.06	2.73	2.59	2.06
EV/Sales Ratio	3.28	3.12	3.17	2.56	2.82	2.65
EV/EBITDA Ratio	9.97	9.51	9.74	8.39	9.52	9.28
EV/EBIT Ratio	17.28	16.47	16.17	14.43	16.71	17.92
EV/FCF Ratio	-	-	209.98	-	38.03	17.80
Debt / Equity Ratio	1.57	1.57	1.61	1.66	1.53	1.63
Debt / EBITDA Ratio	6.58	6.58	6.69	6.98	6.50	7.23
Debt / FCF Ratio	-	-	152.00	-	27.72	14.75
Asset Turnover	0.17	0.17	0.18	0.18	0.18	0.17
Inventory Turnover	7.33	7.33	8.28	10.52	11.13	11.04
Quick Ratio	2.04	2.04	6.01	6.88	6.55	9.04
Current Ratio	2.16	2.16	6.40	7.25	6.88	9.48
Return on Equity (ROE)	8.58%	8.58%	8.86%	8.50%	9.97%	6.37%
Return on Assets (ROA)	2.05%	2.05%	2.18%	2.00%	1.90%	1.59%
Return on Capital (ROIC)	3.21%	3.21%	3.43%	3.26%	3.17%	2.63%
Return on Capital Employed (ROCE)	4.00%	4.00%	3.60%	3.30%	3.20%	2.60%
Earnings Yield	8.94%	10.04%	9.11%	11.63%	11.12%	8.46%
FCF Yield	-1.48%	-1.64%	1.12%	-6.69%	6.52%	15.03%
Dividend Yield	2.69%	3.84%	3.04%	4.14%	3.85%	4.54%
Payout Ratio	30.69%	38.56%	28.86%	36.61%	31.32%	49.47%
Buyback Yield / Dilution	1.42%	1.42%	1.75%	1.90%	2.69%	3.00%
Total Shareholder Return	4.12%	5.26%	4.79%	6.04%	6.54%	7.53%

Updated Feb 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q